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Abstract
We evaluated 6341 consecutive breast cancer samples across multiple platforms to identify biomarkers of po-
tential drug response. Subgroups of triple-negative breast cancers were identiﬁed, with different genemutations,
protein expression levels, and patterns in co-incidence, which might inform individualized treatment options.
Background: Triple-negative breast cancer (TNBC) is an aggressive disease without established targeted treatment
options for patients with metastatic disease. This study was undertaken to evaluate potentially actionable biomarkers
in a large cohort of TNBC and compare them with non-TNBCs. Materials and Methods: We evaluated 6341 (2111
TNBC and 4230 non-TNBC) breast cancer samples at a central laboratory for biomarkers of potential drug response
across multiple platforms, including gene sequencing, protein expression, and gene copy number. Results: TNBC
expresses androgen receptor (AR) in a signiﬁcantly (P < .05) lower percentage of cases (17%) than hormone receptor
(HR)-positive and human epidermal growth factor receptor 2 (HER2)-positive breast carcinomas (59% and 79%,
respectively), and gene comutations were differentially associated with AR-positive versus AR-negative cases. Higher
AR expression levels in TNBC predicted for lower Ki-67 levels. Seventy percent of TNBC harbored a phosphatidyli-
nositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (PIK3CA), v-akt murine thymoma viral oncogene homolog 1
(AKT1), or phosophatase and tensin homolog (PTEN) aberration. TNBC patients had a signiﬁcantly lower PIK3CA
mutation rate (13%) than all other subtypes (P < .05) and a higher tumor protein p53 (TP53) mutation rate (64%) than
the estrogen receptor (ER)-positive cases (approximately 30%; P < .05). Topoisomerase 2 (TOP2A) ampliﬁcation was
observed in 1.3% of TNBC and in 1.6% of HER2-negative, HR-positive cancers; in contrast, HER2-positive,
HR-negative or HR-positive cancers exhibited TOP2A ampliﬁcation in 19% and 40% of cases, respectively (P <.05).
Conclusion: Multi-platform molecular proﬁling identiﬁes subgroups of TNBC with different biomarker proﬁles, sug-
gesting numerous potentially targetable alterations in TNBC. TNBC is further characterized by different gene muta-
tions and proliferative activity relative to AR expression, highlighting a need for comprehensive pathologic examination
with potential to develop different, individualized treatment options.
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Triple-negative breast cancerIntroduction
Breast cancer is the leading cause of cancer-related mortality in
women worldwide.1 It is a heterogeneous disease at the molec-
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474 -cancer (TNBC; estrogen receptor [ER], progesterone receptor [PR],
HER2-negative disease). Molecular subtypes of breast cancer are
also characterized by distinct genetic alterations, among which tu-
mor protein p53 (TP53), phosphatidylinositol-4,5-bisphosphate 3-ki-
nase, catalytic subunit alpha (PIK3CA), Myeloid cell leukemia 1
(MCL1), myelocytomatosis viral oncogene homolog (MYC), and
phosophatase and tensin homolog (PTEN) gene alterations are the
most common in TNBC.2-5
Triple-negative breast cancer is typically an aggressive subtype of
breast cancer. Approximately 30% of TNBC patients experience a
rapid relapse (within 1 to 3 years) after standard adjuvant chemo-
therapy with a median survival of 12 to 18 months with metastatic
disease.6,7 Treatment options are limited because of an absence of the
more common molecular targets in breast cancer (ER, PR, HER2).
The largest comprehensive analysis of TNBC todate8 consisted only of
disease from primary tumors. Few data are available on metastatic and
locally recurrent TNBCs. Therefore, an unmet medical need exists to
identify TNBC biomarkers that might predict therapy response.9
In the present study we reviewed a database of 6341 breast car-
cinomas proﬁled at a single institution (Caris Life Sciences) in an
effort to further differentiate TNBC from other breast cancer sub-
types and to identify potentially targetable molecular characteristics
within TNBC.
Materials and Methods
Tissue Samples
A cohort of 6341 consecutive breast cancer samples, comprising
6206 unique patients, were proﬁled at Caris Life Sciences from
2009 through February 2014. Of those, 5823 unique breast cancer
patients with known ER, PR, and HER2 status were evaluated for
similarities and differences in gene mutations (Sanger or next-
generation sequencing [NGS]), protein expression (immunohisto-
chemistry [IHC]), and/or gene ampliﬁcation using DNA in situ
hybridization (ISH; ﬂuorescent [FISH], and chromogenic [CISH]).Figure 1 Case Distribution. Duplicate Cases and 300 Cases Withou
Grayed Subtypes Were Excluded
Abbreviations: ER ¼ estrogen receptor; Med. ¼ median; PR ¼ progesterone receptor.
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(performed centrally), and HER2/neu IHC or ISH status (Figure 1).
Metaplastic breast cancer cases were excluded; ER and PR were
considered positive when  1% of tumor cells exhibited nuclear
positivity (College of American Pathologists [CAP]/American
Society of Clinical Oncology [ASCO] 2010). HER2/neu was pos-
itive when > 10% of cells exhibited strong complete membranous
staining (score 3þ)10; alternatively, FISH or CISH was used for
evaluation of the HER2/neu (HER2/chromosome 17 centromere
[CEP17] probe); HER2/CEP17 ratio > 2.0 was considered ampli-
ﬁed (CAP/ASCO guideline 2013). Thresholds used for other IHC
and in situ hybridization assays are listed in Supplemental Table 1
in the online version. Proteins evaluated, in addition to androgen
receptor (AR), ER, PR, and HER2, included topoisomerases 1 and
2, v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog
(cKIT), epidermal growth factor receptor (EGFR), PTEN,
O(6)-methylguanine-methyltransferase (MGMT), P-glycoprotein
(PGP), transducin-like enhancer of split 3 (TLE3), ribonucleotide
reductase M1 (RRM1), serum protein acidic and rich in cysteine
(SPARC), tubulin beta-3 chain (TUBB3), excision repair cross-
complementation group 1 (ERCC1), platelet derived growth fac-
tor receptor alpha (PDGFRA), and thymidylate synthase (TS).
Multiplatform Testing
Testing was performed on formalin ﬁxed parafﬁn embedded
tissue samples using the Caris Molecular Intelligence (CMI) tumor
proﬁling service (http://www.carismolecularintelligence.com). CMI
uses multiple standard platforms and methodologies, including
protein expression (IHC), gene mutation analysis (NGS and Sanger
sequencing), and gene copy number alterations (FISH and CISH;
list available at: http://www.carismolecularintelligence.com/next-
generation-sequencing-proﬁle).11
Per clinical recommendations for breast cancer, ER and PR were
considered positive when  1% of tumor cells exhibited nucleart Reportable ER, PR, or HER2 Data Were Not Included in Totals;
Figure 3 Somatic Mutation Frequency in BC Subtypes.
Includes Next-Generation Sequencing (NGS) for All
Genes and Sequencing of BRAF, EGFR, KRAS and
PIK3CA Using Sanger; Not All Tests Were Performed
for All Cases. Genes in Which Mutations Occurred
With an Incidence < 0.5% Are Not Shown (NRAS,
SMARCB1, MPL, NOTCH1, ABL1, HNF1A, BRAF, SMO,
VHL, CSF1R, FGFR2, PDGFRA, PTPN11, ERBB4,
CTNNB1, FGFR1, GNAS, c-KIT). Genes for Which No
Mutations Were Seen in Any of the Subtypes Included
ALK, FLT3, GNA11, JAK2, NPM1, and RET. The
Number in Parentheses Equals the Number of Cases
Evaluated Using NGS
Abbreviations: ER ¼ estrogen receptor; PR ¼ progesterone receptor; TNBC ¼ triple-negative
breast cancer.
Sherri Z. Millis et alpositivity (CAP/ASCO 2010). HER2/neu was positive when > 10%
of cells exhibited strong complete membranous staining (3þ) or
when FISH or CISH evaluation of the HER2/neu (HER-2/CEP17
probe) HER2/CEP17 ratio was > 2.0 (CAP/ASCO guideline 2013).
Depending on tissue availability, physician preference, and
technology standards over the course of sample receipt at the lab-
oratory, the testing breakdown varied by case (TNBC detailed in
Figure 2). For example, gene sequence analysis was performed using
Sanger sequencing on a limited number of relevant genes before the
availability of NGS technology, which then led to hot spot analysis
of larger numbers of genes simultaneously.
All methods used in this study were clinically validated to at least
Clinical Laboratory Improvement Amendments, CAP, and Inter-
national Organization for Standardization (ISO) 15189 standards.
The therapeutic drug associations were determined using recom-
mendations from published clinical evidence, which includes peer-
reviewed literature and/or the National Comprehensive Cancer
Network guidelines,12 not restricted to cancer type. No preclinical
or experimental drug associations were made; however, biomarker
associations with drugs in advanced-stage clinical trials were made.
Statistical Methods
The 2-tail Fisher exact test and c2 test were used to test when
proportions of positive results were different between TNBC and
non-TNBC (signiﬁcance level  .05). JMP version 10.0 (SAS Insti-
tute Inc, Cary, NC) and R version 2.15 (R Foundation for Statistical
Computing, Vienna, Austria) were used for statistical analysis.
Results
The 5823-patient study included 2111 (36%) TNBC patients.
The high percentage of TNBC patients in this breast cancer cohort
is likely due to the aggressive nature of TNBC, which led to a higher
percentage of cases submitted for molecular proﬁling than in the
general breast cancer population. Of the TNBC cohort 1302 (62%)Figure 2 Breakdown of Technology Used and Number of Tests
to Evaluate Triple-Negative Breast Cancer (TNBC)
Tissues. *Sanger Sequencing Was Performed on
PIK3CA, Epidermal Growth Factor Receptor (EGFR),
Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS),
B-Raf Proto-Oncogene (BRAF), and Neuroblastoma
RAS Viral Oncogene Homolog (NRAS). Next-Generation
Sequencing (NGS) Was Performed on 47 Genes, As
Described in the Materials and Methods. Actual Case
Totals Might Differ Between Markers, Because of
Occasional Test Failures of Single Genes
Abbreviations: CISH ¼ Chromogenic In Situ Hybridization; FISH ¼ Fluorescent In Situ Hybrid-
ization; IHC ¼ immunohistochemistry.consisted of tissue from metastatic cancers. Of the overall patient
cohort 560 cases (14%) were HER2-positive, and within that
cohort 229 (4%) were positive for ER and PR (Figure 1).
Multiplatform Proﬁling and Relevance to Therapeutic
Targets
There were 2300 breast cancer cases in this cohort, including 760
TNBC cases, that were proﬁled by either NGS (n ¼ 450) or Sanger
sequencing (n ¼ 310). Mutations were detected in 39 of 45 genes
tested (87%; Figure 3). Because of the extremely low incidence of
many of the mutations, no clear mutation pattern difference was
identiﬁed between the subtypes, nor was a signiﬁcant difference in
the mutational load between metastatic cases and primary breast
cancers identiﬁed across all subtypes, with the exception of TNBC.
The TNBC metastatic tissues had signiﬁcantly more cases with gene
mutations, cases with comutations, and overall more total gene
mutations than did the primary/recurrent TNBCs (215 of 276 vs.
114 of 174 [P ¼ .0005]; 97 of 276 vs. 26 of 174 [P ¼ .0005]; 305
vs. 147 [P ¼ .001], respectively). Notable genes that were mutated
more frequently in metastatic cases included TP53, PIK3CA, and
PTEN (Figure 4).
The most common mutations in TNBC included TP53 (278 of
437; 64%) and PIK3CA (93 of 702; 13%). TP53 mutations were
less frequently identiﬁed in hormone receptor (HR)-positive cases
(P < .05), especially in the absence of HER2 positivity. In contrast,
PIK3CA mutations were 2 to 3 times higher in the non-TNBC
population (P < .05) than in the TNBC group. Compared with
luminal breast cancers (HR-positive), TNBC had a statisticallyClinical Breast Cancer December 2015 - 475
Figure 5 Distribution of PIK3CA Mutations According to Exon
by Breast Cancer Type. Exon 20 Is Indicated in Green;
Exon 9 Is Indicated in Red; All Other Exons Are
Grouped and Indicated in Blue
Abbreviations: ER ¼ estrogen receptor; HR ¼ hormone receptor. P < .05 Between TNBC and
Other Subtypes for a Given Exon.
Figure 4 Comparison of Mutation Frequency Between
Metastatic and Primary/Recurrent Triple-Negative
Breast Cancer (TNBC). Genes That Were Not Mutated
at Different Frequencies Are Not Shown
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TNBC had a statistically signiﬁcant lower frequency of mutations in
exon 9 compared with luminal and HER2-positive/HR-negative
cases. TNBC also had a higher frequency of mutations outside of
hotspot exons 9 and 20, compared with other subtypes (Figure 5).
Phosophatase and tensin homolog protein loss (0 and<50%) was
observed in 66% (1368 of 2069) of TNBC and in 53% (1513 of
2884) of non-TNBC tumors (P < .0001), despite the infrequent
rate of PTEN mutations (4% [78 of 1950]) in both tumor types.
Mutations in another Phosphatidylinositol-4,5-bisphosphate
3-kinase (PI3) kinase pathway gene, v-akt murine thymoma viral
oncogene homolog 1 (AKT1), were not seen in any HER2-positive
cancers, but were seen at low frequency in HER2-negative cancers
(3.8% [14 of 369] in ER-positive/PR-positive; 5.2% [10 of 192] in
ER-positive/PR-negative, and 2.9% [5 of 172] inTNBC).Within the
TNBC cohort, PI3 kinase pathway involvement measured using
either AKT1, PIK3CA, or PTEN aberration was identiﬁed in
70% (1478 of 2111) of cases, regardless of AR expression levels. This
trend in PI3 kinase pathway involvement was seen in HER2-negative
and HR-positive/HER2-positive or -negative cancers as well.
HER2 mutations were found in 9 of 448 TNBCs tested (see
Supplemental Table 2 in the online version), similar to rates in the
other subtypes. Twenty-four HER2 mutations were identiﬁed
across all subtypes, 5 of which were unique to these breast cancers
and had not been observed in 10,000 cases across all solid tumors
tested at this laboratory. Two of these unique HER2 mutations were
found in the TNBC cohort. Of the HER2 mutations in the TNBC
cohort 67% (6 of 9) were observed in primary tumors whereas only
20% (3 of 15) of non-TNBC HER2 mutations were found in
primary sites (P ¼ .036).
In general, mutations in other genes were not frequently
observed. cKIT mutations were very rare in TNBC (1 of 547; 0.2%)
despite the common expression of cKIT protein (329 of 1239;
26%). Adenomatous polyposis coli was found in 3% (14 of 448) ofClinical Breast Cancer December 2015cases, ataxia telangiectasia mutated in 2% (7 of 442), F-box and
WD repeat domain containing 7 in 1% (3/of 447), Harvey rat
sarcoma viral oncogene homolog in 1% (4 of 368), KRAS in 1%
(10 of 739), retinoblastoma 1 in 2% (9 of 445), serine/threonine
kinase 11 in 1% (6 of 418), and BRAF in 0.3% (2 of 743) of cases.
Ten of the 13 mutations identiﬁed in the RAS/RAF pathway were
activating. AR positivity ( 10% cells with nuclear AR) was
signiﬁcantly lower (340 of 1951; 17%) in TNBC (Figure 6) than
in HER2-positive and/or HR-positive tumors (46%-79%,
P< .05).13,14 Additionally, a signiﬁcant difference in the percentage
of AR positivity was seen in the primary/recurrent versus metastatic
TNBC samples (14% [104 of 735] vs. 19% [236 of 1215],
respectively, P ¼ .01).
Androgen receptor status and concurrent PI3 kinase alterations
were also evaluated across subtypes (Table 1). Fifty-eight percent
(1997 of 340) of TNBCs positive for AR also harbored either
PIK3CA or PTEN mutation/protein loss. Similar rates of PIK3CA
and PTEN mutation/protein loss were observed in AR-positive non-
TNBC cancers (58% vs. 59%). Across all subtypes, AR-positive
cases had a 36% (398/1004) PIK3CA mutation rate, and only
9% (47/524) of the AR-negative cases had a PIK3CA mutation,
similar to a recent report.15 The types of PIK3CAmutations differed
between AR-positive and AR-negative cancers (see Supplemental
Table 3 in the online version). AR-negative TNBC cases had a
Figure 6 Protein Biomarkers Identiﬁed Using Immunohistochemistry, Unless Identiﬁed as In Situ Hybridization, Are Compared
Between Triple-Negative Breast Cancer (TNBC), ERD/HER2, ERD/HER2D, and ERL/HER2D Subtypes. Therapies Are Listed
Next to Each Biomarker, Based on Studies Associating These Proteins as Predictors of Response or Resistance, in Other
Cancers
Abbreviation: ER ¼ estrogen receptor.
Sherri Z. Millis et algreater percentage of mutations in exon 20 (68% vs. 62%) than AR-
positive cases, and AR-positive cases had more mutations in exon 9
(24% vs. 19%). As noted, AKT1 mutations were found only in
HER2-negative subtypes; interestingly, these few instances of AKT1
mutations were nearly always mutually exclusive of PIK3CA/PTEN
mutation/loss. Overall, 91% (1921/2111) of TNBC cases had
changes in AR status and/or mutations in PIK3CA/PTEN/AKT1, or
loss of PTEN.
Triple-negative breast cancer with higher degrees of AR positivity
assessed according to Allred score16 exhibited signiﬁcantly lower
proliferation rates (Ki-67) compared with AR-negative TNBC
(P < .05; Figure 7).
Ampliﬁcation of the Topoisomerase 2 (TOP2A) gene was
observed in only 1% (10 of 778) of TNBC and 2% (18 of 1127) of
HER2-negative, HR-positive cancers, despite the common obser-
vation of Topo2a protein expression (67% [865 of 1289] and 41%
[774 of 1869], respectively). HER2-positive, HR-negative or HR-
positive cancers exhibited TOP2A ampliﬁcation in 19% (57 of
303) and 40% (120 of 337) of the cases, respectively (P <.05) andTopo2a protein expression was common (63% [173 of 276] and
56% [156 of 277], respectively).
Epidermal growth factor receptor gene and cMYC were ampliﬁed
in 22% (127 of 566) and 27% (8 of 30) of TNBC and in 23% (38
of 163) and 25% (50 of 199) of HER2-positive breast cancers, and
HR-positive tumors harbored EGFR and cMYC ampliﬁcation in
only 8% (54 of 650) and 13% (82 of 804) of cases, respectively.
Additionally, in TNBC, EGFR ampliﬁcation was associated with a
signiﬁcant decrease in expression of TS ( 1þ and  10%; 26% of
EGFR nonampliﬁed cases vs. 10% of EGFR ampliﬁed cases; P ¼
.0001) and RRM1 ( 2þ and  50%; 36% of EGFR non-
ampliﬁed cases vs. 20% of EGFR ampliﬁed cases; P ¼ .0003,
respectively). Of the EGFR ampliﬁed TNBC 95% overexpressed
TOP2A and 90% were AR-negative. EGFR ampliﬁcation was
almost always associated with HER2 ampliﬁcation in non-TNBC
breast cancers, although the converse was not seen.
Transducin-like enhancer of split 3 (TLE3) overexpression was
observed in 33% (587 of 1772) of TNBC. Signiﬁcantly greater
TLE3 overexpression was observed in HER2-positive andClinical Breast Cancer December 2015 - 477
Table 1 PIK3CA, AKT1, and PTEN Status in TNBC and Compared With Other Subtypes
Molecular Subtype
Total Cases,
AKT1 Mutation
Found/AKT1
Tested, na
Total Cases,
AR and
PIK3CA
Assayed, n
Cases With
PIK3CA
Mutation
Total Cases
With AR
and PTEN
Assayed, n
Cases With
PTEN Loss
(IHC) or
Mutation
Cases With
PIK3CA Mutation
and PTEN Loss
or Mutation
Androgen Receptor-
Positive Cases (IHC)
ERþ/PRþ/HER2 11/294 452 45% 1395 3.4% PTEN mut
50.1% PTEN loss
50.3% Total
8%
ERþ/PR/HER2 6/106 150 37% 530 2.9% PTEN mut
51.5% PTEN loss
51.5% Total
6%
ERþ/PRþ/HER2þ 0/26 116 38% 160 7.7% PTEN mut
43.8% PTEN loss
43.8% Total
16%
ERþ/PR/HER2þ 0/28 76 21% 107 0% PTEN mut
51.4% PTEN loss
51.4% Total
13%
ER/PR/HER2þ 0/33 115 39% 177 3.1% PTEN mut
54.8% PTEN loss
54.8% Total
10%
ER/PR/HER2 9/73 95 36% 340 12.9% PTEN mut
56.5% PTEN loss
57.6% Total
10%
Androgen Receptor-
Negative Cases (IHC)
ERþ/PRþ/HER2 2/72 43 19% 421 4.3% PTEN mut
59.4% PTEN loss
60.1% Total
26%
ERþ/PR/HER2 4/85 114 19% 365 11.0% PTEN mut
59.2% PTEN loss
59.2% Total
10%
ERþ/PRþ/HER2þ 0/6 24 33% 43 0% PTEN mut
65.1% PTEN loss
65.1% Total
29%
ERþ/PR/HER2þ 0/10 39 23% 69 0% PTEN mut
53.6% PTEN loss
53.6% Total
5%
ER/PR/HER2þ 0/33 121 32% 198 0% PTEN mut
68.2% PTEN loss
68.2% Total
18%
ER/PR/HER2 2/372 524 9% 1607 2.0% PTEN mut
69.0% PTEN loss
69.0% Total
5%
Abbreviations: AR ¼ androgen receptor; ER ¼ estrogen receptor; IHC ¼ immunohistochemistry; mut ¼ mutation; n ¼ number tested; PR ¼ progesterone receptor; PTEN ¼ phosophatase and tensin
homolog.
an equal to number tested.
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[147 of 210]; P ¼ .0001). TS overexpression ( 1þ and  10%)
was seen in 26% (489 of 1899) of TNBC cases and in 17% (122/
717) of HER2-positive cases, whereas only 10% (301/3011) of HR-
positive cancers exhibited signiﬁcant TS expression (P < .05). Pgp
overexpression ( 1þ and  10%) was similarly distributed across
molecular subtypes and was generally uncommon (12% of TNBC,
11% of HER2-positive, and 5% of HR-positive cases). The per-
centage of cases that displayed topoisomerase 1 expression ( 2þ
and  30%), RRM1 expression ( 2þ and > 50%), MGMT
expression ( 1þ and > 35%), and SPARC overexpression ( 2þ
and  30%) were fairly evenly distributed across the molecular
subtypes, including TNBC. Other changes in protein expressionClinical Breast Cancer December 2015and or gene ampliﬁcation status associated with potential thera-
peutic options are shown (Figure 6).
Discussion
Protein expression and gene sequencing proﬁling have contrib-
uted signiﬁcantly to the characterization of the genomic and mo-
lecular landscape of breast cancer,9,17 especially in characterization
of primary tumors. However, with few exceptions such as breast
cancer 1 and 2 mutations, a substantial proportion of breast cancer
patients remain without targetable gene mutations, particularly
those with aggressive subtypes such as TNBC. In this study, which
is the largest known cohort published to date (compared with
Lehmann with 587 TNBC18 and Teng with 653 TNBC19), we
Figure 7 (A) Androgen Receptor (AR)-Positive and (B) ARL
(< 10%) Correlation With Ki-67 in Triple-Negative
Breast Cancer
Sherri Z. Millis et alcharacterized breast cancers using multiple platforms to measure
gene mutations, gene ampliﬁcation, and protein expression to
identify potentially actionable targets previously not considered or
not considered in combination. Additionally, we evaluated differ-
ences in mutation rates between primary and metastatic breast
cancers. Analysis of this large cohort, of which 62% presented with
metastatic tissue, identiﬁed numerous predictive biomarkers for
targeted agents, cytotoxic therapies, and suggests potential treatment
combinations.
A limited number of actionable somatic mutations characterize
breast cancers including TNBC.9 In the current study, NGS of
TNBC identiﬁed mutations in 29 of 45 genes tested, and in only
22% of cases tested, of which 15% were potentially clinically
actionable mutations (deﬁned as a mutation for which there is a
Food and Drug Administration-approved therapy). Speciﬁcally,
PIK3CA, PTEN, and APC mutations were the most common in
TNBC using NGS. TP53 mutations, although not considered
clinically actionable, were also commonly seen and have been
associated with poor response to anthracyclines and radiotherapy.20
TP53, PIK3CA, and PTEN were found at greater frequencies in
metastatic TNBC compared with primary disease. All other muta-
tions occurred at very low levels ( 1% of cases), similar to what hasbeen reported in previous studies on somatic mutations in breast
cancer.2,3,8,9,21,22 This afﬁrms the limited number of actionable
targets in TNBC when only gene mutations are evaluated. For
example, we identiﬁed EGFR mutations in only 2 of 466 TNBC
cancers (1 primary and 1 metastatic), in contrast to EGFR gene
ampliﬁcation, which was observed in 22% of TNBC breast cancers.
Germline mutations, including BRCA1/2, were not evaluated.
Somatic BRCA1/2 mutations evaluated at this laboratory were
identiﬁed at an incidence similar to what was previously reported23
and were not a part of this analysis.
Epidermal growth factor receptor ampliﬁcation was also seen at
signiﬁcant rates in other subtypes. Of HER2-positive/HR-negative
breast cancers 23% (30% in primary and 20% in metastatic tissues)
harbored EGFR ampliﬁcations, as did 10% of poor-prognosis ER-
positive breast cancers. These results indicate that single (anti-
EGFR) and dual therapeutic targeting (anti-HER2/EGFR) might
be worthy of exploration in TNBC and HER2-positive patients,
respectively.24
HER2 mutations have been described in a small percentage of
various human tumors including lung, colorectal, head and neck,
ovarian, and gastric carcinomas.25-28 These mutations can also occur
in HER2-ampliﬁed and non-ampliﬁed breast carcinomas,29,30 as
conﬁrmed in a small proportion of the cases in our study. More
HER2 mutations were found in primary TNBCs compared with
other breast cancers, suggesting perturbation of the HER2 pathway
in some TNBC. Inhibition of HER2 mutation neratinib in patients
with HER2 non-ampliﬁed breast cancer is currently being
investigated.29
The proportion of AR positivity in TNBCs (17%) was signiﬁ-
cantly lower than in non-TNBCs (46%-79% range). ER-negative
HER2-positive breast cancers had a signiﬁcantly lower incidence
of AR-positive cases (46%) compared with ER-positive cases (79%).
Expression of AR in breast cancers might be associated with
response to AR inhibitors such as bicalutamide31 or enzalutamide.
An ongoing study with enzalutamide is currently being explored in a
phase II trial in patients with TNBC, and data presented at the San
Antonio Breast Cancer Symposium (SABCS) 2014 showed effec-
tiveness (P5-19-09, Traina, et al. Stage 1 results from MDV3100-
11: A 2-stage study of enzalutamide [ENZA], an AR inhibitor, in
advanced ARþ TNBC). Apocrine breast tumors (AR-positive) tend
to harbor PIK3CA and/or PTEN alterations.13,32 PI3 kinase
pathway inhibitors might be of beneﬁt in combination with in-
hibitors of AR in these patients.13,15 As has been previously re-
ported, our analysis also showed PIK3CA mutant cancers more
commonly expressed AR than do PIK3CA wild type cancers. A
retrospective study showed a signiﬁcant association between AR
positivity and the presence of PIK3CA mutations in ER/PR-
negative, AR-positive tumors.33
Furthermore, we found a 2-fold increased frequency of PIK3CA/
PTEN alterations in metastatic compared with primary TNBCs.
This ﬁnding corroborates previous reports.13,34 Apart from its
potential predictive role, we found higher levels of AR expression to
be signiﬁcantly associated with decreased proliferation in TNBC as
has been recently reported.35-37 This observation highlights the
heterogeneity of TNBC and suggests a potentially more favorable
clinical course in a subset of more indolent AR-positive
TNBCs.13,38-40Clinical Breast Cancer December 2015 - 479
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and TNBC, yet it is not known which subtypes of patients might
beneﬁt and should therefore be selected for clinical trial enrollment
of antiandrogen therapy. A relationship between the degree of AR
positivity and tumor biology (eg, Ki-67), has been elucidated for
ER-positive disease, yet few data exist from central reference labo-
ratories that describe this relationship. This is the only study to date
with a large number of TNBC with Ki-67 and AR status evaluated
in a single laboratory.
Among cytotoxic agent response biomarkers, our study revealed
high topo1 expression in TNBC, which could potentially reﬁne the
use of therapy with topoisomerase 1 inhibitors in breast cancers.
Some topoisomerase 1 inhibitors (eg, etirinotecan, irinotecan) have
been previously evaluated in metastatic breast cancer and have ev-
idence of activity, including in TNBC.24 Topo1 has not been
shown to select for TNBC or non-TNBC patients that beneﬁt from
topoisomerase 1 inhibitors, but this hypothesis is being pursued
in the ongoing phase III studies of etirinotecan in TNBC
(NCT01492101).
We also noted that TOP2A ampliﬁcation is more common in
ER-positive breast cancers. Whether this marker predicts for beneﬁt
from anthracycline therapy will be evaluated in the ongoing Na-
tional Surgical Adjuvant Breast and Bowel Project B49 study. The
ﬁnding that 91% of TNBC have either increased AR protein
expression, loss of PTEN, or mutations in PIK3CA, PTEN, or
ATK1 indicates potential for new therapies or combination thera-
pies for most of the patients. When other changes in protein
expression in this patient cohort are added to the evaluation, 98% of
the analyzed patient population has potentially targetable bio-
markers, which is comparable with the non-TNBC population.
Early evidence supports predictive utility for many of the bio-
markers reported in this study, and studies are ongoing to evaluate
these proteins as predictors of response and resistance. The protein
status is not used as part of standard of care algorithms, but rather as
guidance when standard agents have failed the patient.Conclusion
In summary, evaluating genomic alterations and protein expres-
sion identiﬁes potentially actionable targets in up to 98% of TNBC
cases. Targetable mutations/amplicons such as PIK3CA and EGFR
were identiﬁed, and expression of AR, Ki-67, PTEN, and topo-
isomerase 1. Although treatment and outcomes were not available
for this large retrospective analysis, future studies using biomarker
status as part of trials will bring the ﬁeld forward and answer some of
the outstanding questions relative to the potential therapeutic op-
tions identiﬁed in this study.
Clinical Practice Points
 Triple-negative breast cancer is a heterogeneous disease associated
with poor prognosis and having in common a lack of expression of
ER, PR, and HER2 proteins. Some molecular characterization has
been performed, speciﬁcally in primary TNBC.
 Differences in molecular characteristics have been found between
primary versus metastatic disease.
 Novel patterns in co-incidence or exclusivity of incidence of
genomic and/or proteomic biomarker alterations have been found.Clinical Breast Cancer December 2015 Triple-negative breast cancer molecular subtypes will dictate
different responses to conventional therapeutic strategies, different
therapies, and novel therapies based on identiﬁed molecular targets.Disclosure
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Supplemental Table 1 Immunohistochemistry Thresholds
Biomarker Localization IHC Thresholds (Staining Intensity and Percent Tumor)
Androgen receptor Nuclear ¼ 0þ or <10% or 1þ and 10%
MET proto-oncogene, receptor tyrosine kinase Membrane <50% or <2þ or 2þ and 50%
Epidermal growth factor receptor Membrane ¼ 0þ or ¼ 1þ and ¼ 10% or
¼ 2þ and ¼ 10%
Estrogen receptor Nuclear ¼ 0þ or ¼ 0% or 1þ and 1%
Progesterone receptor Nuclear ¼ 0þ or ¼ 0% or 1þ and 1%
Human epidermal growth factor receptor 2 Membrane 1þ or ¼ 2þ and 10% or 3þ
and >10%
O(6)-methylguanine-methyltransferase Nuclear ¼ 0þ or 35% or 1þ and >35%
P-glycoprotein Membrane ¼ 0þ or <10% or 1þ and 10%
Phosophatase and tensin homolog protein Nuclear, membrane,
cytoplasm
¼ 0þ or 50% or 1þ and >50%
Ribonucleotide reductase M1 Cytoplasm <2þ or <50% or 2þ and 50%
Serum protein acidic and rich in cysteine Cytoplasm <30% or <2þ or 2þ and 30%
Transducin-like enhancer of split 3 Nuclear <30% or <2þ or 2þ and 30%
Topoisomerase 2 Nuclear ¼ 0þ or <10% or 1þ and 10%
Topoisomerase 1 Nuclear ¼ 0þ or <30% or <2þ or 2þ and 30%
Thymidylate synthase Nuclear, cytoplasm ¼ 0þ or 3þ and <10% or 1þ and 10%
Tubulin beta-3 chain Cytoplasm <30% or <2þ or 2þ and 30%
xcision repair cross-complementation group 1 Nuclear <2þ or 3þ and <10% or ¼ 2þ and <50% or 3þ
and 10% or 2þ and 50%
Marker of proliferation Nuclear ¼ 0þ or <15% or 1þ and 20%
v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene
homolog
Membrane, cytoplasm ¼ 0þ and ¼ 100% or 2þ
and 30%
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Supplemental Table 2 HER2 Mutations Identiﬁed in Tissues Across Breast Cancer Subtypes
Molecular Subtype Cases, n % L755Sa D769Yb R816Gc D769Hd I767Me T875Ic
P780_Y781
insGSPc S779Fc R814Cc
ERþ/PRþ/HER2 33 6.1 2 (1’)
ERþ/PR/HER2 128 10.7 1 (’) 2
ERþ/PRþ/HER2þ 364 0.8 1 1 1
ERþ/PR/HER2þ 188 2.1 2 1
dbl -L755s
1
ER/PR/HER2þ 68 4.4 2 (1’) 1
ER/PR/HER2 448 2.0 6 (4’) 1 (1’) 1 1 (1’)
(’) indicates primary tissue and number of times identiﬁed.
aSeen in 19% of HER2 mutations across tumor types (in 10,000 cases tested at Caris).
bSeen in 8% of HER2 mutations across tumor types (in 10,000 cases tested at Caris).
cNot seen elsewhere across tumor types (in 10,000 cases tested at Caris).
dSeen in 4% of HER2 mutations (1 ¼ bladder, 1 ¼ kidney, 1 ¼ cancer of unknown primary; in 10,000 cases tested at Caris).
eSeen in 4% of HER2 mutations (presumed benign1 ¼ CRC,1 ¼ ovarian,1 ¼ endometrial; in 10,000 cases tested at Caris).
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Supplemental Table 3 Speciﬁc PIK3CA Mutations Identiﬁed
PIK3CA Mutation,
Protein Change
ARL (48 Cases;
2 With 2), n ARL, %
ARD (37 Cases,
2 With 2), n ARD, % Exon
P104_V105delinsL 1 2.1 1
G106R 1 2.7
G106V 1 2.7
N107S 1 2.7
R108_E109delinsQ 1 2.1
V346del 1 2.7 4
E418_L422delinsV 1 2.1 7
E418K 1 2.1
H419_C420del 1 2.7
C420R 1 2.1
E542K 3 6.3 1 2.7 9
E545A 1 2.1
E545G 1 2.1
E545K 4 8.3 8 21.6
E726K 1 2.1 13
H1047L 4 8.3 1 2.7 20
H1047R 29 60.4 21 56.8
G1049R 1 2.7
Comparison between AR triple-negative breast cancer (TNBC) cases and ARþ TNBC cases.
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